Home > Riviste > Minerva Endocrinologica > Fascicoli precedenti > Minerva Endocrinologica 2018 March;43(1) > Minerva Endocrinologica 2018 March;43(1):50-6

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

REVIEW  THE EVOLUTION OF IVF 

Minerva Endocrinologica 2018 March;43(1):50-6

DOI: 10.23736/S0391-1977.17.02638-4

Copyright © 2017 EDIZIONI MINERVA MEDICA

lingua: Inglese

Ovarian hyperstimulation syndrome management strategies: where are we going?

Ashley M. ESKEW, Kenan R. OMURTAG

Department of Reproductive Endocrinology and Infertility, Washington University School of Medicine, St. Louis, MO, USA


PDF


Ovarian hyperstimulation syndrome (OHSS) is one of the most frequent, serious and potentially lethal iatrogenic complications of controlled ovarian stimulation. Despite extensive research, the exact pathogenesis of this syndrome remains less clear, but there appears to be a relationship of increased vascular permeability mediated by HCG and other downstream mediators. Adequate experience with ovulation induction therapy and identifying patients with known risk factors are essential in preventing OHSS. As this is a completely iatrogenic disease numerous strategies have been investigated to help decrease the risk of OHSS and their effects on pregnancy and live birth rate. What follows is a review of the common strategies apply today to minimize risk of OHSS in patients undergoing assisted reproductive technologies.


KEY WORDS: Ovarian hyperstimulation syndrome - Gonadotropins - Leuprolide

inizio pagina